Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting - Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...

EBMT ADAPTS COURSE DELIVERY WITH D2L TO ENSURE CONTINUITY OF TRAINING AND ASSESSMENT FOR ALL ITS MEMBERS DURING THE PANDEMIC London, Sept. 02, 2021 (GLOBE NEWSWIRE) -- D2L, a global learning technology leader, announced today that its customer, the European Society for Blood and Marrow Transplantation (EBMT), is using the...